Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

MAHA Report's Fake Citations A Red Flag For Experts No Photo Available

Yeji Jesse Lee

Fake and misinterpreted citations in a recent federal report focused on chronic disease in the U.S. are raising alarm bells that feder... (more story)

Health Policy Expert On The Changing Vaccine Landscape No Photo Available

Yeji Jesse Lee

KFF's Jen Kates talks about the changing vaccine landscape, the trickle-down effects of the Trump administration's policies and what s... (more story)

Monthly Merger Review Snapshot No Photo Available

Matthew Perlman

The Federal Trade Commission finally dropped its long-pending challenge of Microsoft's purchase of video game developer Activision Bli... (more story)